← SynDRA
TAPOTOCLAX
SynDRA canonical compound SYN0039876 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | MCL1 |
|---|
| Mechanism of action | MCL1 inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- BCL2
- BCL2L1
- CCND1
- CYP1A2
- CYP2C19
- CYP2C9
- CYP2D6
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- AMG-176
- MCL-1 INHIBITOR AMG-176
- 11
- AMG176
- JQNINBDKGLWYMU-GEAQBIRJSA-N
- SCHEMBL17550216
- EX-A2666
- HY-101565
- CS-0021721
- Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-
- AMG 176
- MCL-1 inhibitor AMG-176
- RefChem:187435
- Tapotoclax [USAN]
- Tapotoclax [WHO-DD]
- TAPOTOCLAX [INN]
- UNII-97W7N9T08G
- orb1707668
- SCHEMBL29378243
- SCHEMBL29553502
- SCHEMBL29723360
- AMG-176;CS-2836
- BDBM50514200
- NSC804041
- WHO 11092
- AKOS040741103
- NSC-804041
- NCGC00689100-01
- AC-36265
- MS-30719
- VF8
Look up TAPOTOCLAX in the interactive SynDRA portal →